Comparing a combined pill with separate medicines for coronary artery disease
Tests one combined pill against separate medicines in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Cross-over Study of Coronary Risk Factors With a Polypill
Key facts
- Where
- Gijón, SpainSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease who already take the Trinomia polypill to prevent further heart problems and can attend 6 visits.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- People who take the polypill for secondary prevention (to prevent further heart problems after coronary artery disease).
- Earlier treatment
- Must already be treated with the Trinomia® polypill, in any of its presentations. Must not take any other blood-thinning drug besides acetylsalicylic acid (low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants).
Main reasons for not taking part
- Contraindication to any component of the polypill
- Planned coronary revascularization
- Coronary stent implanted in the last 12 months
- Condition limiting life expectancy to less than 1 year
- Already taking part in another clinical trial
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitario de CabueñesGijón, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT05030818
- Record updated
- 5 August 2025
- Original description
Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.Read full original descriptionShow less
Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill
Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.
Inclusion: Patients over 18 years of age. Patients under treatment with the Trinomia® polypill in any of its presentations for indication of secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent.
Exclusion: Patients who do not sign the informed consent. Patients with an inability to understand and comply with the protocol. Patients with contraindication to any component of the polypill. Patients who are already participating in another clinical trial. Patients with any condition that limits life expectancy to <1 year. Patients with programmed coronary revascularization. Patients with coronary stent implantation in the last 12 months. Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is, low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.